Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models

Clinical and Experimental Metastasis

Volumn 29, Issue 6, 2012, Pages 585-601

  Zollo, Massimo ^a,b   Di Dato, Valeria ^a,b   Spano, Daniela ^a,b   De Martino, Daniela ^a,b   Liguori, Lucia ^a   Marino, Natascia ^a,b   Vastolo, Viviana ^a,b   Navas, Luigi ^a,b   Garrone, Beatrice ^c   Mangano, Giorgina ^c   Biondi, Giuseppe ^c   Guglielmotti, Angelo ^c  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Università Politecnica delle Marche ACRAF Gruppo Angelini   (Italy)

Author keywords

Breast; MCP 1 CCL2; Myeloid derived suppressor cells; Prostate; Tumor associated macrophages; Xenograft

Indexed keywords

BINDARIT; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL INFILTRATION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAMMARY GLAND; METASTASIS; MONOCYTE; MOUSE; NONHUMAN; PRIMARY TUMOR; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CCL2; FEMALE; HUMANS; INDAZOLES; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NF-KAPPA B; PROPIONATES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84863724938     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9473-5     Document Type: Article

References (73)

1. Havens AM et al (2008) An in vivo mouse model for human prostate cancer metastasis. Neoplasia 10(4):371-380
2. Spano D, Zollo M (2012) Tumor microenvironment: a main actor in the metastasis process. Clin Exp Metastasis 29(4):381-395
3. Pikarsky E et al (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431(7007):461-466
4. Mizutani K et al (2009) The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia 11(11):1235-1242
5. Aggarwal MM et al (2010) Measurement of the bottom quark contribution to nonphotonic electron production in p? p collisions at sqrt[s] = 200 GeV. Phys Rev Lett 105(20):202301
6. Lu X, Kang Y (2009) Chemokine (C-C motif) ligand 2 engages CCR2? stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem 284(42): 29087-29096
7. Zhang J, Lu Y, Pienta KJ (2010) Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 102(8):522-528
8. Takahashi M et al (2009) Chemokine CCL2/MCP-1 negatively regulates metastasis in a highly bone marrow-metastatic mouse breast cancer model. Clin Exp Metastasis 26(7):817-828
9. Nam JS et al (2006) Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res 66(14):7176-7184
10. Zhang J, Patel L, Pienta KJ (2010) CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 21(1):41-48
11. Loberg RD et al (2007) CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 9(7):556-562
12. Molloy AP et al (2009) Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int J Cancer 124(2):326-332
13. Qian BZ et al (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475(7355):222-225
14. Salcedo R et al (2000) Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96(1):34-40
15. Saji H et al (2001) Significant correlation of monocyte chemo-attractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92(5):1085-1091
16. Mirolo M et al (2008) Impact of the anti-inflammatory agent bindarit on the chemokinome: selective inhibition of the mono-cyte chemotactic proteins. Eur Cytokine Netw 19(3):119-122
17. Mora E et al (2012) Bindarit: an anti-inflammatory small molecule that modulates the NFkappaB pathway. Cell Cycle 11(1): 159-169
18. Bhatia M et al (2008) Treatment with bindarit, an inhibitor of MCP-1 synthesis, protects mice against trinitrobenzene sulfonic acid-induced colitis. Inflamm Res 57(10):464-471
19. Bhatia M et al (2005) Treatment with bindarit, a blocker of MCP-1 synthesis, protects mice against acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 288(6):G1259-G1265
20. Ble A et al (2011) Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. Am J Nephrol 34(4):367-372
21. Guglielmotti A et al (2002) Amelioration of rat adjuvant arthritis by therapeutic treatment with bindarit, an inhibitor of MCP-1 and TNF-alpha production. Inflamm Res 51(5):252-258
22. Ialenti A et al (2011) Inhibition of in-stent stenosis by oral administration of bindarit in porcine coronary arteries. Arterios-cler Thromb Vasc Biol 31(11):2448-2454
23. Rulli NE et al (2009) Amelioration of alphavirus-induced arthritis and myositis in a mouse model by treatment with bindarit, an inhibitor of monocyte chemotactic proteins. Arthritis Rheum 60(8):2513-2523
24. Rulli NE et al (2011) Protection from arthritis and myositis in a mouse model of acute chikungunya virus disease by bindarit, an inhibitor of monocyte chemotactic protein-1 synthesis. J Infect Dis 204(7):1026-1030
25. Zhou GX et al (2010) Protective effects of MCP-1 inhibitor on a rat model of severe acute pancreatitis. Hepatobiliary Pancreat Dis Int 9(2):201-207
26. Gazzaniga S et al (2007) Targeting tumor-associated macrophages and inhibitionof MCP-1 reduce angiogenesis and tumor growthina human melanoma xenograft. J Invest Dermatol 127(8):2031-2041
27. D'Angelo A, Garzia L, André A, Carotenuto P, Aglio V, Guardiola O, Arrigoni G, Cossu A, Palmieri G, Aravind L, Zollo M (2004) Prune cAMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis. Cancer Cell 5(2):137-149
28. Roca H, Varsos Z, Pienta KJ (2008) CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem 283(36):25057-25073
29. Roca H et al (2008) CCL2, survivin and autophagy: new links with implications in human cancer. Autophagy 4(7):969-971
30. Yang L et al (2008) Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1?CD11b? myeloid cells that promote metastasis. Cancer Cell 13(1):23-35
31. Mantovani A (2010) Molecular pathways linking inflammation and cancer. Curr Mol Med 10(4):369-373
32. Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4(7):540-550
33. Lazennec G, Richmond A (2010) Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 16(3):133-144
34. Monti P et al (2003) The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 63(21): 7451-7461
35. Fujimoto H et al (2009) Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer 125(6):1276-1284
36. Ueno T et al (2000) Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6(8):3282-3289
37. Spano D, Heckc C, De Antonellisa P, Christofori G, Zollo M (2012). Molecular Networks that Regulate Cancer Metastasis. Semin Cancer Biol. doi:10.1016/j.semcancer.2012.03.006. Accessed 30 March 2012
38. Soria G, Ben-Baruch A (2008) The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267(2):271-285
39. Li X et al (2009) A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res 69(4): 1685-1692
40. Lu Y et al (2009) Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis 26(2): 161-169
41. Soria G et al (2008) Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine 44(1):191-200
42. Lu Y et al (2006) Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66(12):1311-1318
43. Lu Y et al (2007) CCR2 expression correlates with prostate cancer progression. J Cell Biochem 101(3):676-685
44. Lu Y et al (2007) Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res 67(8):3646-3653
45. Izhak L et al (2012) Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis. PLoS One 7(1):e28305
46. van Golen KL et al (2008) CCL2 induces prostate cancer trans-endothelial cell migration via activation of the small GTPase Rac. J Cell Biochem 104(5):1587-1597
47. Lu Y et al (2007) PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteo-clast differentiation and prostate cancer cell proliferation and invasion in vitro. Int J Cancer 121(4):724-733
48. Qian DZ et al (2010) CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxic-ity. Prostate 70(4):433-442
49. Hembruff SL et al (2010) Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and-independent mechanisms. Neoplasia 12(5): 425-433
50. Loberg RD et al (2007) Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 67(19):9417-9424
51. Zoja C et al (1998) Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int 53(3):726-734
52. Guglielmotti A et al (1993) Chronic inflammatory response in the rat can be blocked by bindarit. Biochem Mol Biol Int 29(4): 747-756
53. Cioli V et al (1992) A new protein antidenaturant agent, bindarit, reduces secondary phase of adjuvant arthritis in rats. J Rheumatol 19(11):1735-1742
54. Craig MJ, Loberg RD (2006) CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer Metastasis Rev 25(4):611-619
55. Rodrigues LR et al (2007) The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 16(6):1087-1097
56. Rittling SR, Chambers AF (2004) Role of osteopontin in tumour progression. Br J Cancer 90(10):1877-1881
57. Solinas G et al (2010) Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol 185(1):642-652
58. DuPre SA, Redelman D, Hunter KW Jr (2007) The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci. Int J Exp Pathol 88(5):351-360
59. Morales JK et al (2010) GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1-bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat 123(1):39-49
60. Roland CL et al (2009) Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 8(7):1761-1771
61. Melancon MP et al (2010) Targeted imaging of tumor-associated M2 macrophages using a macromolecular contrast agent PG-Gd-NIR813. Biomaterials 31(25):6567-6573
62. Polfliet MM et al (2006) The rat macrophage scavenger receptor CD163: expression, regulation and role in inflammatory mediator production. Immunobiology 211(6-8):419-425
63. van Dongen M et al (2010) Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer 127(4): 899-909
64. Sanchez-Martin L et al (2011) The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood 117(1):88-97
65. Shabo I et al (2008) Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer 123(4): 780-786
66. Asano K et al (2011) CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity 34(1):85-95
67. Lau SK, Chu PG, Weiss LM (2004) CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol 122(5):794-801
68. Barral P et al (2010) CD169(?) macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nat Immunol 11(4):303-312
69. Allavena P et al (2008) The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 222:155-161
70. Roy PG, Thompson AM (2006) Cyclin D1 and breast cancer. Breast 15(6):718-727
71. Fu M et al (2004) Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145(12):5439-5447
72. Neumeister P et al (2003) Cyclin D1 governs adhesion and motility of macrophages. Mol Biol Cell 14(5):2005-2015
73. Tsou CL et al (2007) Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 117(4):902-909